http://www.hcv.ru/articles/pdf/IFN-RBV_vs_PEG-RBV.pdf

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

https://www.journal-of-hepatology.eu/article/0168-8278(95)80226-6/pdf

Histological grading and staging of chronic hepatitis.

https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.510240201

An algorithm for the grading of activity in chronic hepatitis C

https://www.aspe.vb.it/it/downloads/Brunt%20classificazione%20NASH.pdf

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

BACKGROUND:
Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C. OBJECTIVE:
To assess the efficacy and safety of 24 or 48 weeks of treatment with peginterferon-alpha2a plus a low or standard dose of ribavirin. DESIGN:
Randomized, double-blind trial. SETTING:
99 international centers. PATIENTS: 1311 patients with chronic hepatitis C. PATIENTS:
1311 patients with chronic hepatitis C. INTERVENTION:
Peginterferon-?2a, 180 ?/wk, for 24 or 48 weeks plus a low-dose (800 mg/d) or standard weight-based dose (1000 or 1200 mg/d) of ribavirin. Measurement: Sustained virologic response: undetectable HCV RNA concentration at the end of treatment and during 12 to 24 weeks of follow-up. RESULTS:
Overall and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribavirin was statistically superior to low-dose ribavirin. In patients with HCV genotype 1, absolute differences in sustained virologic response rates between 48 and 24 weeks of treatment were 11.2% (95% CI, 3.6% to 18.9%) and 11.9% (CI, 4.7% to 18.9%), respectively, between standard- and low-dose ribavirin. Sustained virologic response rates for peginterferon-alpha2a and standard-dose ribavirin for 48 weeks were 63% (CI, 59% to 68%) overall and 52% (CI, 46% to 58%) in patients with HCV genotype 1. In patients with HCV genotypes 2 or 3, the sustained virologic response rates in the 4 treatment groups were not statistically significantly different. CONCLUSION:
Treatment with peginterferon-?2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.1840010511

Jerome Wollman

Papers

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis